Overview of protease inhibitors

Journal of the American Pharmaceutical Association

Volumn 37, Issue 5, 1997, Pages 543-551

  Pakyz, A ^a   Israel, D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE; BIOLOGICAL MARKER;

DRUG EFFICACY; DRUG RESISTANCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MYALGIA; PACKAGING; PARESTHESIA; RASH; REVIEW; TASTE DISORDER; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION;

BIOLOGICAL MARKERS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0031217223     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1086-5802(16)30247-9     Document Type: Review

References (37)

1. Update: trends in AIDS incidence, deaths, and prevalence—United States MMWR 46 8 1996 165 173
2. Update: mortality attributable to HIV infection among persons aged 25-44 years—United States MMWR 45 6 1994 121 125
3. M.S. Hirsch R.T. D'Aquila Therapy for human immunodeficiency virus infection N Engl J Med. 328 1993 1686 1695
4. U.S. Department of Health Human Services Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents June 19, 1997 Washington, DC:DHHS
5. F.D.A. Public Health Advisory Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV) June 11, 1997 Rockville, Md:Food and Drug Administration Center for Drug Evaluation and Research
6. A. Wlodawer Proteinase inhibitors: the result of rational drug design Pharmacother. 14 1994 9S 20S
7. G. Moyle B. Gazzard Current knowledge and future prospects for the use of HIV protease inhibitors Drugs. 51 1996 701 712
8. N.E. Kohl E.A. Emilio W.A. Schleif Active human immunodeficiency virus protease is required for viral infectivity Proc Natl Acad Sci USA. 85 1988 4686 4690
9. T. Robins J. Plattner HIV protease inhibitors: their anti-HIV activity and potential role in treatment J Acquir Immune Defic Syndr. 6 1993 162 170
10. V. Stella Update on HIV protease inhibitors AIDS Clinical Care. 7 1996 79 84
11. S.L. Nightingale From the Food and Drug Administration JAMA. 275 1996 273
12. Saquinavir package insert 1996 Roche Laboratories Nutley, NJ
13. J.W. Mellors C.R. Rinaldo P. Gupta Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science. 272 1996 1167 1170
14. R.T. Schooley Correlation between viral load measurements and outcome in clinical trials of antiviral drugs AIDS. 9 1995 S15 S19
15. J.W. Mellors L.A. Kingsley C.R. Rinaldo Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med. 122 1995 573 579
16. C.C.J. Carpenter M.A. Fischl S.M. Hammer Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society—USA panel JAMA. 277 1997 1962 1969
17. C.C.J. Carpenter M.A. Fischl S.M. Hammer Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel JAMA. 276 1996 146 154
18. Indinavir package insert 1996 Merck & Co West Point, Pa
19. Ritonavir package insert 1996 Abbott Laboratories North Chicago, III
20. Nelfinavir package insert. La Jolla, Calif: Agouron Pharmaceuticals; 1997.
21. S.A. Danner A. Carr J.M. Leonard A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease N Engl J Med. 333 1995 1528 1533
22. M. Markowitz M. Saag W.G. Powderly A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med. 333 1995 1534 1539
23. A.C. Collier R.W. Coombs D.A. Schoenfeld Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zal-citabine N Engl J Med. 334 1996 1011 1017
24. S. Noble D. Faulds Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection Drugs. 52 1996 93 112
25. Roche invirase/HIVID combo reduces AIDS mortality 68% FDC Reports—The Pink Sheet. 58 2 1996 T&G-12
26. Saquinavir product information 1996 Roche Laboratories Nutley, NJ
27. M. Pierce S. Crampton D. Henry A randomized trial of clarithromycin as prophylaxis against disseminated mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome N Engl J Med. 335 1996 384 391
28. D.V. Havlir M.P. Dube F.R. Sattler Prophylaxis against disseminated mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both N Engl J Med. 335 1996 392 398
29. S.G. Deeks M. Smith M. Holodniy HIV-1 protease inhibitors: a review for clinicians JAMA. 277 1997 145 153
30. Cohen C, Sun E, Cameron W, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; New Orleans. September 15-8, 1996; Abstract LB7b.
31. Ritonavir product information 1996 Abbott Laboratories North Chicago, III
32. The Indinavir (MK 639) Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies. XI International Conference on AIDS: July 7-12, 1996; Abstract Mo.B.174.
33. Nelfinavir product information 1997 Agouron Pharmaceuticals; La Jolla, Calif
34. J. Leland The end of AIDS? Newsweek. December 2 1996 64 73
35. G.A. Maltz Merck opens indinavir distribution to more pharmacies Pharmacy Today 3 3 1997 1 17
36. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin MMWR. 45 2 1996 921 926
37. CDC lists options for managing rifampin, protease inhibitor therapy Am J Health Syst Pharm. 53 1996 2942 2943